

ROBERTA MUSSINELLI

Nationality: Italian

Email address: roberta.mussinelli@gmail.com

EDUCATION AND TRAINING

PhD in Internal Medicine and Medical Therapy

Nov 2011 – Mar 2020

University of Pavia, Corso Strada Nuova, 65, 27100 Pavia (Italy)

<https://web.unipv.it/>

Specialization in Internal Medicine

2011 – 2017

University of Pavia, Corso Strada Nuova, 65, 27100 Pavia (Italy) and

Fondazione IRCCS Policlinico San Matteo, Viale Golgi 19, 27100 Pavia (Italy)

<https://web.unipv.it/>

<http://www.sanmatteo.org/site/home.html>

Final grade: Cum laude

Degree in Medicine and Surgery

2005 – 2011

University of Pavia, Corso Strada Nuova, 65, 27100 Pavia (Italy)

<https://web.unipv.it/>

Final grade: Cum laude

From October 2009 to July 2010 Medical student at Rheinische Friedrich-Wilhelm Universität in Bonn (Germany) with Erasmus program.

WORK EXPERIENCE

Consultant at Amyloid Centre

Nov 2017 – Current

Fondazione IRCCS Policlinico San Matteo, viale Golgi, 19, 27100 Pavia (Italy)

Clinic and Echocardiographic evaluation of patients with amyloidosis.

Sub-investigator in clinical trials of novel drugs for treating amyloidosis.

Visiting Researcher

Jan 2017 – Jun 2017

Amyloidosis Center, Boston University School of Medicine, Boston, MA (USA)

Echocardiographic evaluation with focus on left ventricular and left atrial strain analysis in patient with cardiac amyloidosis.

LANGUAGE SKILLS

Mother tongue: Italian

Other languages: English

LISTENING C2; READING C2; WRITING; C1

SPOKEN PRODUCTION C1; SPOKEN INTERACTION C1.

DIGITAL SKILLS

Excellent use of all Microsoft Office® packages, End Note®, statistical program as MedCalc®, and RedCap®.

Good competence in transthoracic echocardiography, ventricular strain analysis (Qlab di Philips®, Tomtec® Image Arena V4.6, syngo Velocity Vector Imaging di Siemens®) and atrial strain analysis (Tomtec® Image Arena V4.6).

SCIENTIFIC ACTIVITY

Her main research focus is the diagnosis and treatment of the different forms of cardiac amyloidosis and the management of the supportive therapy.

She is part of the International Society of Amyloidosis since 2014 and a member of Italian Society of Internal Medicine (SIMI), American Society of Echocardiography (ASE) and Italian Society of Echocardiography and Cardiovascular Imaging (SIECVI).

She has participated as Sub-investigator in more than 5 clinical trials on novel drugs for the treatment of hereditary amyloidosis or wild-type TTR amyloidosis and in more than 3 clinical trials regarding AL amyloidosis therapy.

PUBLICATIONS

RELATED TO MAIN RESEARCH FOCUS

Current and Emerging Therapies for Hereditary Transthyretin Amyloidosis: Strides Towards a Brighter Future. Obici L, Mussinelli R. Neurotherapeutics. 2021 Nov 30.
DOI: 10.1007/s13311-021-01154-y

New effective treatment options reinforce disease awareness: the case of transthyretin cardiac amyloidosis. Perlini S, Mussinelli R, Salinaro F. Eur J Heart Fail. 2021 Feb.
DOI: 10.1002/ehfj.2111

Description of a large cohort of Caucasian patients with V122I ATTRv amyloidosis: Neurological and cardiological features. Gentile L, Di Bella G, Minutoli F, Cucinotta F, Obici L, Mussinelli R, Arimatea I, Russo M, Toscano A, Vita G, Mazzeo A. J Peripher Nerv Syst. 2020 Sep.
DOI: 10.1111/jns.12385

Baseline ECG Features and Arrhythmic Profile in Transthyretin Versus Light Chain Cardiac Amyloidosis. Cappelli F, Vignini E, Martone R, Perlini S, Mussinelli R, Sabena A, Morini S, Gabriele M, Tabocchi G, Bartolini S, Lossi A, Nardi G, Marchionni N, Di Mario C, Olivetto I, Perfetto F. Circ Heart Fail. 2020 Mar.
DOI: 10.1161/CIRCHEARTFAILURE.119.006619

Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis. Lohrmann G, Pipilas A, Mussinelli R, Gopal DM, Berk JL, Connors LH, Vellanki N, Hellawell J, Siddiqi OK, Fox J, Maurer MS, Ruberg FL. J Card Fail. 2020 Sep.
DOI: 10.1016/j.cardfail.2019.11.024

An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis. Milani P, Mussinelli R, Perlini S, Palladini G, Obici L. Expert Opin Pharmacother. 2019 Dec.
DOI: 10.1080/14656566.2019.1671352

Real-world versus trial patients with transthyretin amyloid cardiomyopathy. Canepa M, Tini G, Musumeci B, Cappelli F, Milandri A, Mussinelli R, Autore C, Perfetto F, Rapezzi C, Perlini S. Eur J Heart Fail. 2019 Nov.
DOI: 10.1002/ehfj.1563

Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. Lillenes B, Ruberg FL, Mussinelli R, Doros G, Sancherawala V. Blood. 2019 Jan 17.
DOI: 10.1182/blood-2018-06-858951

Independent Prognostic Value Of Stroke Volume Index In Patients With Immunoglobulin Light Chain Amyloidosis. Milani P, Dispenzieri A, Scott CG, Gertz MA, Perlini S, Mussinelli R, Lacy MQ, Buadi FK, Kumar S, Maurer MS, Merlini G, Hayman SR, Leung N, Dingli D, Klarich KW, Lust JA, Lin Y, Kapoor P, Go RS, Pellikka PA, Hwa YL, Zeldenrust SR, Kyle RA, Rajkumar SV, Grogan M. Circ Cardiovasc Imaging. 2018 May.
DOI: 10.1161/CIRCIMAGING.117.006588

New And Evolving Concepts Regarding The Prognosis And Treatment Of Cardiac Amyloidosis. Perlini S, Mussinelli R, Salinaro F. Curr Heart Fail Rep. 2016 Dec.
DOI: 10.1007/s11897-016-0311-y

Prognostic Value Of Depressed Midwall Systolic Function In Cardiac Light-Chain Amyloidosis. Perlini S, Salinaro F, Musca F, Mussinelli R, Boldrini M, Raimondi A, Milani P, Foli A, Cappelli F, Perfetto F, Palladini G, Rapezzi C, Merlini G. J Hypertens. 2014 May.
DOI: 10.1097/HJH.0000000000000120

Prevalence And Prognostic Value Of Conduction Disturbances At The Time Of Diagnosis Of Cardiac AL Amyloidosis. Boldrini M, Salinaro F, Mussinelli R, Raimondi A, Alogna A, Musca F, Palladini G, Merlini G, Perlini S. Ann Noninvasive Electrocardiol. 2013 Jul.
DOI: 10.1111/anec.12032

Diagnostic And Prognostic Value Of Low QRS Voltages In Cardiac AL Amyloidosis. Mussinelli R, Salinaro F, Alogna A, Boldrini M, Raimondi A, Musca F, Palladini G, Merlini G, Perlini S. Ann Noninvasive Electrocardiol. 2013 May.
DOI: 10.1111/anec.12036

Prognostic Value Of Fragmented QRS In Cardiac AL Amyloidosis. Perlini S, Salinaro F, Cappelli F, Perfetto F, Bergesio F, Alogna A, Mussinelli R, Boldrini M, Raimondi A, Musca F, Palladini G, Merlini G. Int J Cardiol. 2013 Sep 1.
DOI: 10.1016/j.ijcard.2012.05.097

NOT RELATED TO MAIN RESEARCH FOCUS

Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering. J Healthc Eng. 2021 Jun 25.
DOI: 10.1155/2021/5556207

Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study. Front Med (Lausanne). 2021 Jun 9.
DOI: 10.3389/fmed.2021.639970

Persistence of disease flares is associated with an inadequate colchicine dose in familial Mediterranean fever: A national multicenter longitudinal study. J Allergy Clin Immunol Pract. 2021 Aug. DOI: 10.1016/j.jaip.2021.03.048

RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a metaanalysis of 19 studies. Vascui Pharmacol. 2020 Dec.
DOI: 10.1016/j.vph.2020.106805

Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study. Nutr Metab Cardiovasc Dis. 2020 Oct 30.
DOI: 10.1016/j.numecd.2020.07.031

Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study. Eur J Intern Med. 2020 Dec.
DOI: 10.1016/j.ejim.2020.08.019

Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension. Hypertension. 2020 Aug.
DOI: 10.1161/HYPERTENSIONAHA.120.15324

Lung Ultrasound In Internal Medicine: A Bedside Help To Increase Accuracy In The Diagnosis Of Dyspnea. Eur J Intern Med. 2017 Dec.
DOI: 10.1016/j.ejim.2017.07.034

23 Febbraio 2022

Roberto M. M. M.

